(Q37416512)

20 August 2017

1 reference

title

Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors (English)

1 reference

20 August 2017

main subject

venous thromboembolism

1 reference

Ted Wun

1

1 reference

20 August 2017

Richard H White

series ordinal

2

1 reference

20 August 2017

publication date

1 January 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

27 Suppl 1

1 reference

20 August 2017

page(s)

63-74

1 reference

Cancer and thrombosis: from molecular mechanisms to clinical presentations

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Trousseau's syndrome: multiple definitions and multiple mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Malignancies, prothrombotic mutations, and the risk of venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Cancer and venous thromboembolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Epidemiology of thrombosis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Prevalence and significance of asymptomatic venous thromboembolic disease found on oncologic staging CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Pathophysiology of the thrombophilic state in the cancer patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Incidence of venous thromboembolism and the impact on survival in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Venous thromboembolism in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

The incidence of venous thromboembolism among patients with primary lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Epidemiology of venous thromboembolism in 9489 patients with malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Prognostic importance of comorbidity in a hospital-based cancer registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Comorbidity measures for use with administrative data

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

The thrombophilic state induced by therapeutic agents in the cancer patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Chemotherapy-induced thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Arterial and venous thrombotic complications with thalidomide in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Risk of thrombosis with lenalidomide and its prevention with aspirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Bevacizumab, bleeding, thrombosis, and warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Development and validation of a predictive model for chemotherapy-associated thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Risk factors for venous thromboembolic events in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

P-selectin mediates adhesion of leukocytes, platelets, and cancer cells in inflammation, thrombosis, and cancer growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Microparticle-associated tissue factor activity: a link between cancer and thrombosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Deep vein thrombosis and cancer: survival, recurrence, and anticoagulant choices

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Prognosis of Cancers Associated with Venous Thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

Thromboembolism in Adults with Acute Lymphoblastic Leukemia During Induction with L-Asparaginase-containing Multi-agent Regimens: Incidence, Risk Factors, and Possible Role of Antithrombin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F07357900802656681

10.1080/07357900802656681

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference